Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
GB:0HD2
Stock Latest News
The Fly
BioCryst appoints Sandeep Menon as chief research and development officer
5d ago
ALNY
BCRX
Premium
The Fly
Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26
12d ago
ALNY
Premium
The Fly
Alnylam presents new data on potential of zilebesiran for hypertension
12d ago
ALNY
Premium
Ratings
Alnylam Pharmaceuticals: Solid TTR Demand but Near‑Term Headwinds Justify Hold Rating
12d ago
ALNY
Premium
Ratings
Alnylam Buy Rating Backed by Expanding ATTR-CM Opportunity, Durable Amvuttra Leadership, and Long-Term Growth Visibility
17d ago
ALNY
Premium
Ratings
Alnylam Pharmaceuticals: Underpenetrated TTR Market and Strong Commercial Execution Support Buy Rating
17d ago
ALNY
Premium
Ratings
Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential
17d ago
ALNY
Premium
The Fly
Alnylam announces set of efforts to improve care for patients with ATTR-CM
18d ago
ALNY
Premium
The Fly
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
26d ago
ECL
ETN
Premium
The Fly
Alnylam downgraded to Hold from Buy at Jefferies
26d ago
ALNY
Premium
The Fly
Tenaya Therapeutics enters research collaboration with Alnylam
1M ago
ALNY
TNYA
Premium
Company Announcements
Alnylam Grants CEO New Performance-Based Equity Award
1M ago
8K
ALNY
Premium
Ratings
Balancing Short-Term Amvuttra Headwinds Against Solid TTR Growth: Rationale for Maintaining a Hold Rating
1M ago
ALNY
Premium
Ratings
Alnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating
2M ago
ALNY
Premium
The Fly
Alnylam price target raised to $429 from $415 at Canaccord
2M ago
ALNY
Premium
The Fly
Alnylam price target raised to $429 from $415 at Canaccord
2M ago
ALNY
Premium
The Fly
Alnylam price target lowered to $249 from $415 at Canaccord
2M ago
ALNY
Premium
The Fly
Alnylam upgraded to Buy from Hold at Freedom Capital
2M ago
ALNY
Premium
The Fly
Alnylam price target lowered to $360 from $408 at Morgan Stanley
2M ago
ALNY
Premium
The Fly
Alnylam price target lowered to $451 from $491 at Bernstein
2M ago
ALNY
Premium
The Fly
Alnylam price target lowered to $425 from $475 at Chardan
2M ago
ALNY
Premium
Company Announcements
Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
2M ago
ALNY
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
